Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL29385217 | 0.92 | HIF1A (0.64) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| 8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL94250 | 0.92 | HIF1A (0.64) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| 8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL27581572 | 0.91 | HIF1A (0.56) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| 8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL8140547 | 0.91 | HIF1A (0.62) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| SCHEMBL112181 | 0.81 | HIF1A (0.64) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| SCHEMBL28471201 | 0.80 | HSP90AA1 (0.62) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| SCHEMBL4461500 | 0.79 | COMT (0.64) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| SCHEMBL8883998 | 0.79 | ENPP2 (0.60) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| SCHEMBL8882696 | 0.77 | ENPP2 (0.58) | HIF1AALOX15HPGDALDH1A1HSD17B10 | |
| SCHEMBL8882706 | 0.77 | ENPP2 (0.58) | HIF1AALOX15HPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105271246-B | A kind of method that chloro disilane is prepared using polysilicon by-product | 宁夏胜蓝化工环保科技有限公司 | 2017-12-22 | — | — | CN | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| CN-105271246-A | Method for preparing chlorinated disilane by utilization of polysilicon byproducts | NINGXIA SHENGLAN CHEMICAL ENVIRONMENTAL PROT TECHNOLOGY CO LTD | 2016-01-27 | — | — | CN | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-8975278-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-03-10 | — | — | US | disclosed |
| US-20150025108-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20060089380-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LTD. (AU) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | HIF1A 1928/4885ALOX15 2258/4885HPGD 165/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | HIF1A 1928/4885ALOX15 2258/4885HPGD 165/4885 |
| US-20150025108-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | HIF1A 1928/4885ALOX15 2258/4885HPGD 165/4885 |
| US-20060089380-A1 | 8-Hydroxy quinoline derivatives | PARK7, HTT, SNCA | HIF1A 752/4885ALOX15 1070/4885HPGD 123/4885 |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | HIF1A 1928/4885ALOX15 2258/4885HPGD 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.